Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by BlueFranky on Feb 02, 2023 5:13pm

Quick poll

A question everyone:

When do you think we will achieve

BTD

.. and then AA
Comment by sade69 on Feb 02, 2023 5:23pm
Exacly when everything will be in place, Why bother?
Comment by N0taP00p on Feb 02, 2023 6:24pm
Q2 '23 and Q4'24
Comment by CancerSlayer on Feb 02, 2023 8:29pm
  I think an expedited approval in whatever form is almost a foregone conclusion based on the optimized data trends...I'm not too concerned about the "if" & I never like to predict the "when" in this business, but I'd certainly consider an approval to be a "near-term" event when viewed in the context of the number of years most here have been ...more  
Comment by ScienceFirst on Feb 02, 2023 8:41pm
Well said Cancer.Slayer. Princess Margaret Cancer Center, the only Cancer Center outside the US, will out of no doubt help it become mainstream as the Ontario government has invested a lot of grants in us.  Medical tourism is also an important economic industry. We could compare our PDT/PDC NMIBC treatment to what LASIK brought to the ophthalmology industry in terms of revolution.
Comment by CancerSlayer on Feb 02, 2023 9:06pm
Good points...forgot about the impact of medical tourism.  Seems like a lot of patients stateside would be more than happy to visit Toronto once or twice for a quick bladder tune-up...followed by a hearty bowl of poutine ; )
Comment by Rumpl3StiltSkin on Feb 03, 2023 10:59am
'We all want a quick ROI'  Ha! Nice one Slayer, Made me spit out some coffee when I read that...
Comment by Rumpl3StiltSkin on Feb 03, 2023 10:56am
Early Q2 '23, Early Q3 '23...  :-)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250